145 related articles for article (PubMed ID: 33998364)
1. Incorporating propensity scores for evidence synthesis under bayesian framework: review and recommendations for clinical studies.
Lin J; Lin J
J Biopharm Stat; 2022 Jan; 32(1):53-74. PubMed ID: 33998364
[TBL] [Abstract][Full Text] [Related]
2. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
3. A Bayesian nonparametric causal inference model for synthesizing randomized clinical trial and real-world evidence.
Wang C; Rosner GL
Stat Med; 2019 Jun; 38(14):2573-2588. PubMed ID: 30883861
[TBL] [Abstract][Full Text] [Related]
4. Covariate handling approaches in combination with dynamic borrowing for hybrid control studies.
Fu C; Pang H; Zhou S; Zhu J
Pharm Stat; 2023; 22(4):619-632. PubMed ID: 36882191
[TBL] [Abstract][Full Text] [Related]
5. Propensity-score-based meta-analytic predictive prior for incorporating real-world and historical data.
Liu M; Bunn V; Hupf B; Lin J; Lin J
Stat Med; 2021 Sep; 40(22):4794-4808. PubMed ID: 34126656
[TBL] [Abstract][Full Text] [Related]
6. Propensity score stratified MAP prior and posterior inference for incorporating information across multiple potentially heterogeneous data sources.
Zhu AY; Roy D; Zhu Z; Sailer MO
J Biopharm Stat; 2024 Mar; 34(2):190-204. PubMed ID: 36882957
[TBL] [Abstract][Full Text] [Related]
7. Propensity score-integrated power prior approach for augmenting the control arm of a randomized controlled trial by incorporating multiple external data sources.
Lu N; Wang C; Chen WC; Li H; Song C; Tiwari R; Xu Y; Yue LQ
J Biopharm Stat; 2022 Jan; 32(1):158-169. PubMed ID: 34756158
[TBL] [Abstract][Full Text] [Related]
8. Bayesian adaptive randomization design incorporating propensity score-matched historical controls.
Sawamoto R; Oba K; Matsuyama Y
Pharm Stat; 2022 Sep; 21(5):1074-1089. PubMed ID: 35278032
[TBL] [Abstract][Full Text] [Related]
9. Incorporating Bayesian methods into the propensity score matching framework: A no-treatment effect safety analysis.
Li L; Donnell ET
Accid Anal Prev; 2020 Sep; 145():105691. PubMed ID: 32711214
[TBL] [Abstract][Full Text] [Related]
10. Propensity-score-based priors for Bayesian augmented control design.
Lin J; Gamalo-Siebers M; Tiwari R
Pharm Stat; 2019 Mar; 18(2):223-238. PubMed ID: 30537087
[TBL] [Abstract][Full Text] [Related]
11. Leveraging external evidence using Bayesian hierarchical model and propensity score in the presence of covariates.
Chen X; Yao Y; Wang L; Mukhopadhyay S
Contemp Clin Trials; 2023 Sep; 132():107301. PubMed ID: 37467950
[TBL] [Abstract][Full Text] [Related]
12. Utility of propensity score-based Bayesian borrowing of external adult data in pediatric trials: A pragmatic evaluation through a case study in acute lymphoblastic leukemia (ALL).
Majumdar A; Rothwell R; Reaman G; Ahlberg C; Roy P
J Biopharm Stat; 2023 Nov; 33(6):737-751. PubMed ID: 36600441
[TBL] [Abstract][Full Text] [Related]
13. Propensity score-incorporated adaptive design approaches when incorporating real-world data.
Lu N; Chen WC; Li H; Song C; Tiwari R; Wang C; Xu Y; Yue LQ
Pharm Stat; 2024; 23(2):204-218. PubMed ID: 38014753
[TBL] [Abstract][Full Text] [Related]
14. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
[TBL] [Abstract][Full Text] [Related]
15. Semi-supervised mixture multi-source exchangeability model for leveraging real-world data in clinical trials.
Haine LMF; Murry TA; Nahra R; Touloumi G; Fernández-Cruz E; Petoumenos K; Koopmeiners JS
Biostatistics; 2023 Sep; ():. PubMed ID: 37697901
[TBL] [Abstract][Full Text] [Related]
16. Propensity score-integrated Bayesian prior approaches for augmented control designs: a simulation study.
Wang X; Suttner L; Jemielita T; Li X
J Biopharm Stat; 2022 Jan; 32(1):170-190. PubMed ID: 34939894
[TBL] [Abstract][Full Text] [Related]
17. Dynamic incorporation of real world evidence within the framework of adaptive design.
Lin J; Liao R; Gamalo-Siebers M
J Biopharm Stat; 2022 Nov; 32(6):986-998. PubMed ID: 35730907
[TBL] [Abstract][Full Text] [Related]
18. Practical considerations of utilizing propensity score methods in clinical development using real-world and historical data.
Li Q; Lin J; Chi A; Davies S
Contemp Clin Trials; 2020 Oct; 97():106123. PubMed ID: 32853779
[TBL] [Abstract][Full Text] [Related]
19. Beyond Randomized Clinical Trials: Use of External Controls.
Schmidli H; Häring DA; Thomas M; Cassidy A; Weber S; Bretz F
Clin Pharmacol Ther; 2020 Apr; 107(4):806-816. PubMed ID: 31725899
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
